{
    "info": {
        "nct_id": "NCT03733990",
        "official_title": "A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours",
        "inclusion_criteria": "Subjects must meet all of the following inclusion criteria to be eligible for participation in the clinical trial:\n\n1. Written Informed Consent\n2. Aged ≥ 18 years male or female\n3. Tumour sample should be collected during screening period. If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III\n4. Life expectancy > 12 weeks\n5. Histologically confirmed advanced (inoperable or metastatic) malignancies without standard therapeutic options available:\n\n   * Hepatocellular carcinoma\n   * Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma\n   * Colorectal adenocarcinoma\n   * Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer\n   * Pancreatic ductal adenocarcinoma\n   * Immunotherapy (IO) refractory cutaneous melanoma (progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)\n   * Uveal melanoma in Parts II and III\n   * Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III\n   * ER+ breast cancer in Parts II and III\n   * Anaplastic thyroid cancer in Parts II and III\n6. ECOG performance status 0 or 1\n7. Measurable disease in Parts II and III\n8. Adequate bone marrow, liver and kidney function defined as Blood white blood cell ≥ lower limit of normal Blood neutrophil count ≥ 1x10(9)/L Blood platelet count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L Blood haemoglobin ≥ 9.0 g/dL Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula AST ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases are present) ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present) Bilirubin ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.\n9. Women of child-bearing potential must have a negative pregnancy test in serum prior to trial entry\n10. Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment\n\nExclusion Criteria;\n\n1. Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration\n2. Any immunotherapy within preceding 6 weeks from the first IMP administration\n3. Investigational therapy or major surgery within 4 weeks from the date of consent\n4. Active clinically serious infection > Grade 2 NCI-CTCAE version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent\n5. Brain metastases\n6. Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade ≤ 2 alopecia, neuropathy or thyroid disorders)\n7. Pregnant or lactating women\n8. History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse\n9. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial\n10. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment\n11. Confirmed human immunodeficiency virus infection\n12. Symptomatic cytomegalovirus infection\n13. Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)\n14. The subject requires systemic corticosteroid or other immunosuppressive treatment\n15. Subjects with organ transplants\n16. Subjects in dialysis\n17. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit\n18. Subject is unwilling or unable to comply with treatment and trial instructions\n19. Subjects with known hypersensitivity to the IMP or any of the pharmaceutical ingredients\n\nSpecific Additional Exclusion Criteria for Hepatobiliary Cancers\n\n1. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry)\n2. Hepatic encephalopathy\n3. Ascites refractory to diuretic therapy\n4. Child-Pugh score ≥ 7\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. Ascites refractory to diuretic therapy",
            "criterions": [
                {
                    "exact_snippets": "Ascites refractory to diuretic therapy",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness to diuretic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Subjects with organ transplants",
            "criterions": [
                {
                    "exact_snippets": "Subjects with organ transplants",
                    "criterion": "organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Colorectal adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anaplastic thyroid cancer in Parts II and III",
            "criterions": [
                {
                    "exact_snippets": "Anaplastic thyroid cancer",
                    "criterion": "anaplastic thyroid cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in Parts II and III",
                    "criterion": "study part",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "Part II",
                                "Part III"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Aged ≥ 18 years male or female",
            "criterions": [
                {
                    "exact_snippets": "Aged ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit",
            "criterions": [
                {
                    "exact_snippets": "Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit",
                    "criterion": "use of live (attenuated) vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": [
                                "30 days prior to the start of study treatment",
                                "during treatment",
                                "until last visit"
                            ]
                        },
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III",
            "criterions": [
                {
                    "exact_snippets": "Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction)",
                    "criterion": "gastric adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adenocarcinoma of the distal esophagus / GE junction",
                    "criterion": "adenocarcinoma of the distal esophagus or gastroesophageal junction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatocellular carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Hepatocellular carcinoma",
                    "criterion": "hepatocellular carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Hepatic encephalopathy",
            "criterions": [
                {
                    "exact_snippets": "Hepatic encephalopathy",
                    "criterion": "hepatic encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. ECOG performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration",
            "criterions": [
                {
                    "exact_snippets": "Less than 21 days since the last dose of intravenous anticancer chemotherapy",
                    "criterion": "time since last dose of intravenous anticancer chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration",
                    "criterion": "time since last dose of small molecule targeted therapy or oral anticancer chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "half-lives"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)",
            "criterions": [
                {
                    "exact_snippets": "Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)",
                    "criterion": "active auto-immune disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "type I diabetes",
                                "celiac disease",
                                "hypothyroidism requiring only hormone replacement",
                                "vitiligo",
                                "psoriasis",
                                "alopecia"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment",
            "criterions": [
                {
                    "exact_snippets": "Any medical condition that the Investigator considers significant to compromise the safety of the subject",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment of significance for safety",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any medical condition that ... impairs the interpretation of IMP toxicity assessment",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "impairs interpretation of IMP toxicity assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Active clinically serious infection > Grade 2 NCI-CTCAE version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent",
            "criterions": [
                {
                    "exact_snippets": "Active clinically serious infection > Grade 2 NCI-CTCAE version 5.0 ... within preceding 2 weeks from the date of consent",
                    "criterion": "clinically serious infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "NCI-CTCAE Grade"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks (from date of consent)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer",
            "criterions": [
                {
                    "exact_snippets": "Serous poorly differentiated (Grade 3) ovarian adenocarcinoma",
                    "criterion": "ovarian adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": "serous"
                        },
                        {
                            "requirement_type": "differentiation grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undifferentiated ovarian cancer",
                    "criterion": "ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "differentiation",
                            "expected_value": "undifferentiated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunotherapy (IO) refractory cutaneous melanoma (progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)",
            "criterions": [
                {
                    "exact_snippets": "Immunotherapy (IO) refractory cutaneous melanoma",
                    "criterion": "cutaneous melanoma",
                    "requirements": [
                        {
                            "requirement_type": "immunotherapy refractory status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy",
                    "criterion": "disease progression after specific immunotherapies",
                    "requirements": [
                        {
                            "requirement_type": "progression after therapy",
                            "expected_value": [
                                "PD-1 antibody therapy",
                                "PD-L1 antibody therapy",
                                "CTLA-4 antibody therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse",
            "criterions": [
                {
                    "exact_snippets": "History of second malignancy",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for non-melanotic skin cancer",
                    "criterion": "non-melanotic skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for ... cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for ... superficial bladder cancer",
                    "criterion": "superficial bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other malignancy treated previously with curative intent and more than three years without relapse",
                    "criterion": "other malignancy (treated with curative intent)",
                    "requirements": [
                        {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "time_since_treatment_without_relapse",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Investigational therapy or major surgery within 4 weeks from the date of consent",
            "criterions": [
                {
                    "exact_snippets": "Investigational therapy ... within 4 weeks from the date of consent",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "major surgery within 4 weeks from the date of consent",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pancreatic ductal adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Pancreatic ductal adenocarcinoma",
                    "criterion": "pancreatic ductal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Symptomatic cytomegalovirus infection",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic cytomegalovirus infection",
                    "criterion": "cytomegalovirus infection",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Measurable disease in Parts II and III",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease in Parts II and III",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "study part",
                            "expected_value": [
                                "Part II",
                                "Part III"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ER+ breast cancer in Parts II and III",
            "criterions": [
                {
                    "exact_snippets": "ER+ breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "in Parts II and III",
                    "criterion": "study part",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "Part II",
                                "Part III"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Pregnant or lactating women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Women of child-bearing potential must have a negative pregnancy test in serum prior to trial entry",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential",
                    "criterion": "child-bearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test in serum prior to trial entry",
                    "criterion": "pregnancy test (serum)",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to trial entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate bone marrow, liver and kidney function defined as Blood white blood cell ≥ lower limit of normal Blood neutrophil count ≥ 1x10(9)/L Blood platelet count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L Blood haemoglobin ≥ 9.0 g/dL Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula AST ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases are present) ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present) Bilirubin ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.",
            "criterions": [
                {
                    "exact_snippets": "Blood white blood cell ≥ lower limit of normal",
                    "criterion": "blood white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "lower limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Blood neutrophil count ≥ 1x10(9)/L",
                    "criterion": "blood neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "x10(9)/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Blood platelet count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L",
                    "criterion": "blood platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "x10(9)/L"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for HCC)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 50,
                                        "unit": "x10(9)/L"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Blood haemoglobin ≥ 9.0 g/dL",
                    "criterion": "blood haemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases are present)",
                    "criterion": "AST (aspartate aminotransferase)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (when HCC or hepatic metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present)",
                    "criterion": "ALT (alanine aminotransferase)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (when HCC or hepatic metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Bilirubin ≤ 1.5 X ULN",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Albumin ≥ 3.0 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Any immunotherapy within preceding 6 weeks from the first IMP administration",
            "criterions": [
                {
                    "exact_snippets": "Any immunotherapy within preceding 6 weeks from the first IMP administration",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Written Informed Consent",
            "criterions": [
                {
                    "exact_snippets": "Written Informed Consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Life expectancy > 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy > 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Subjects with known hypersensitivity to the IMP or any of the pharmaceutical ingredients",
            "criterions": [
                {
                    "exact_snippets": "known hypersensitivity to the IMP",
                    "criterion": "hypersensitivity to the IMP",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... any of the pharmaceutical ingredients",
                    "criterion": "hypersensitivity to any of the pharmaceutical ingredients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade ≤ 2 alopecia, neuropathy or thyroid disorders)",
            "criterions": [
                {
                    "exact_snippets": "Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0",
                    "criterion": "adverse events from previous therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "NCI-CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except Grade ≤ 2 alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "NCI-CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except Grade ≤ 2 ... neuropathy",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "NCI-CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except Grade ≤ 2 ... thyroid disorders",
                    "criterion": "thyroid disorders",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "NCI-CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. The subject requires systemic corticosteroid or other immunosuppressive treatment",
            "criterions": [
                {
                    "exact_snippets": "requires systemic corticosteroid or other immunosuppressive treatment",
                    "criterion": "systemic corticosteroid or other immunosuppressive treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial",
            "criterions": [
                {
                    "exact_snippets": "Evidence of severe or uncontrolled systemic diseases",
                    "criterion": "systemic diseases",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive cardiac failure New York Heart Association (NYHA) class 2",
                    "criterion": "congestive cardiac failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Myocardial Infarction (MI) within 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial",
                    "criterion": "laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "makes it undesirable for the subject to participate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Child-Pugh score ≥ 7",
            "criterions": [
                {
                    "exact_snippets": "Child-Pugh score ≥ 7",
                    "criterion": "Child-Pugh score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential ... must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment",
                    "criterion": "contraception use (women of child-bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": [
                                "for the duration of the trial",
                                "for three months after the completion of treatment"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment",
                    "criterion": "contraception use (men with partners of child-bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": [
                                "for the duration of the trial",
                                "for three months after the completion of treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Subject is unwilling or unable to comply with treatment and trial instructions",
            "criterions": [
                {
                    "exact_snippets": "Subject is unwilling ... to comply with treatment and trial instructions",
                    "criterion": "willingness to comply with treatment and trial instructions",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject is ... unable to comply with treatment and trial instructions",
                    "criterion": "ability to comply with treatment and trial instructions",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uveal melanoma in Parts II and III",
            "criterions": [
                {
                    "exact_snippets": "Uveal melanoma in Parts II and III",
                    "criterion": "uveal melanoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "study part",
                            "expected_value": [
                                "Part II",
                                "Part III"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Histologically confirmed advanced (inoperable or metastatic) malignancies without standard therapeutic options available:",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed advanced (inoperable or metastatic) malignancies",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "inoperable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without standard therapeutic options available",
                    "criterion": "standard therapeutic options",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Tumour sample should be collected during screening period. If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III",
            "criterions": [
                {
                    "exact_snippets": "Tumour sample should be collected during screening period.",
                    "criterion": "tumour sample",
                    "requirements": [
                        {
                            "requirement_type": "collection timing",
                            "expected_value": "during screening period"
                        }
                    ]
                },
                {
                    "exact_snippets": "If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used.",
                    "criterion": "tumour biopsy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III",
                    "criterion": "tumour sample requirement",
                    "requirements": [
                        {
                            "requirement_type": "optional",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "certain subjects in Part III"
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Subjects in dialysis",
            "criterions": [
                {
                    "exact_snippets": "Subjects in dialysis",
                    "criterion": "dialysis status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Specific Additional Exclusion Criteria for Hepatobiliary Cancers",
            "criterions": [
                {
                    "exact_snippets": "Specific Additional Exclusion Criteria for Hepatobiliary Cancers",
                    "criterion": "hepatobiliary cancers",
                    "requirements": [
                        {
                            "requirement_type": "exclusion criteria",
                            "expected_value": "specific additional"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry)",
            "criterions": [
                {
                    "exact_snippets": "Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC",
                    "criterion": "ablative therapy for HCC",
                    "requirements": [
                        {
                            "requirement_type": "history of ablative therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ablative therapy type",
                            "expected_value": [
                                "Radio Frequency Ablation",
                                "Percutaneous Ethanol Injection"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry",
                    "criterion": "target lesion(s) treatment status and timing",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "not treated"
                        },
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Gallbladder cancer",
                    "criterion": "gallbladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intra- or extrahepatic cholangiocarcinoma",
                    "criterion": "cholangiocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "intrahepatic",
                                "extrahepatic"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Confirmed human immunodeficiency virus infection",
            "criterions": [
                {
                    "exact_snippets": "Confirmed human immunodeficiency virus infection",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Subjects must meet all of the following inclusion criteria to be eligible for participation in the clinical trial:",
            "criterions": []
        },
        {
            "line": "Exclusion Criteria;",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}